Johnson & Johnson stock holds firm after July earnings beat
Published on 08/18/2026 at 09:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson (US4781601046) stock opened at $262.43 on August 18, 2026, with a market cap of $632.43 billion and a 52-week range of $173.33 to $274.90. The most recent earnings report, issued on July 15, 2026, showed $2.90 in adjusted EPS on $25.31 billion in revenue, both ahead of consensus.
Earnings and guidance
The July quarter also marked 6.6% year-over-year revenue growth, while management kept FY 2026 guidance at $11.60 to $11.75 in EPS. That midpoint implies a clear comparison with the quarter just reported: actual EPS of $2.90 versus analyst expectations of $2.84, a beat of $0.06.
For investors, the key number is not just the quarter itself but the full-year frame. Analysts in the same day-set now expect $11.61 in EPS for the current year, which sits inside the company's own guidance band.
Market setup
TradingKey showed the shares at $262.535 on August 17, 2026, after a 0.84% rise, with a previous close of $260.350 and a 52-week high of $251.710 listed in the same market snapshot. That leaves the stock above both its 50-day average of $252.52 and its 200-day average of $241.60 in the MarketBeat data set.
The ownership backdrop is also still heavy, with institutional investors holding 69.55% of the shares in the MarketBeat filing summary. Insider transactions in that same report included a July 30 sale by Representative Richard McCormick, disclosed on August 14, 2026, for between $1,001 and $15,000 worth of stock.
Dividend and product line
The latest dividend disclosure sets a $1.34 quarterly payment for shareholders of record on August 25, 2026, with an ex-dividend date on the same day and payment on September 8, 2026. On an annualized basis, that works out to $5.36 per share and a 2.0% yield in the cited market snapshot.
Johnson & Johnson's pharmaceuticals unit remains the main earnings engine, with immunology, oncology, infectious disease and neuroscience still central to the product mix. That mix matters because the July quarter's 6.6% revenue growth came despite pressure from STELARA and still left full-year EPS guidance intact.
Stock level
Johnson & Johnson shares traded at $262.43 on August 18, 2026, versus a 52-week range of $173.33 to $274.90 in the cited market data. The stock also sat above its 50-day and 200-day averages, which keeps the recent price action tied to the post-earnings setup rather than a single-day move.
More on Johnson & Johnson stock
Company: Johnson & Johnson
ISIN: US4781601046
Ticker: JNJ
Exchange: NYSE
Price (as of August 18, 2026): $262.43 USD
Market cap: $632.43 billion (as of August 18, 2026)
Sector / Industry: Health Care / Pharmaceuticals
Index membership: Dow Jones Industrial Average
